Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Victoza LEADER trial of 9,000 adults with type 2 diabetes found that drug significantly reduced the risk of heart attack or stroke.
Read More »Victoza LEADER Trial Top-Line Results Announced
GLP-1 Agonist: the Potential New Replacement
Could medication exhibit a much desired side effect with once weekly administration?
Read More »Liraglutide Lacks HbA1c Control in Type 1 Diabetes
New study of normal-weight patients suggests weight reduction, insulin requirements.
Read More »Liraglutide Success Shown Dependent on Early Weight Loss
Patients who responded to medication had greater improvement in cardiometabolic risk factors.
Read More »Study Shows Liraglutide Helps To Reduce Sleepiness
Quality of life in obese patients with type 2 diabetes improved.
Read More »Risks and Benefits of GLP-1s
Systemic review, network meta-analysis found treatment resulted in greatest reductions in HbA1c, fasting blood glucose, and body weight.
Read More »Victoza Vs. SGLT-2 inhibitor for Better BG Control
Safety, efficacy of these new classes of diabetic medication require more detailed investigation.
Read More »The Present and Future of Insulin Therapy Part 19
In this week's Homerun Slides, the philosophy for the reduced need for insulin in type 2 patients and the potential benefits of combining GLP-1-based therapies with insulin.
Read More »Pancreatic Cancer Not Associated with Incretin Drugs
Study results indicate that risk increased similarly for all glucose lowering agents.
Read More »The Present and Future of Insulin Therapy Part 14
In this week's Homerun Slides, the effectiveness of Lixisenatide when added to basal insulin, and strategies for avoiding or minimizing the GI effects of GLP-1.
Read More »